Samsung Biologics employs a range of advanced technologies to enhance the development and manufacturing of biologics. Their services include comprehensive development processes such as cell line development, process development, and analytical development, all designed to ensure high-quality outcomes. The company utilizes a phase-appropriate approach that emphasizes quality by design, leveraging design-of-experiment techniques and extensive in-house analytical capabilities. Notably, their S-CHOice® platform, powered by transposase technology, enhances productivity and flexibility in biomanufacturing, allowing for optimized operations and reliable production of large molecule drug substances.

In addition to development services, Samsung Biologics offers state-of-the-art CGMP-compliant manufacturing facilities that adhere to stringent regulatory standards. Their manufacturing capabilities encompass both drug substance and drug product services, including aseptic filling and lyophilization. The company is also focused on new modalities, such as antibody-drug conjugates (ADCs) and mRNA technologies, which are critical for advancing therapeutic options. By integrating quality assurance and control throughout their processes, Samsung Biologics ensures that their products meet the highest standards of safety and efficacy, ultimately supporting their mission to expedite the drug development journey for their clients.

South Korea

Samsung Biologics is a fully integrated CDMO offering state-of-the-art contract development and manufacturing services. With proven regulatory approvals, the largest capacity, and the fastest throughput, Samsung Biologics is an award-winning partner of choice and is uniquely able to support the development and manufacturing of biologics products at every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide. 

Samsung Biologics

Company Details